Pressmeddelande -

TATAA Biocenter and BTU develops Two-tailed PCR for microRNA analysis offering superior sensitivity and specificity.

TATAA Biocenter and the Institute of Biotechnology, BIOCEV, have developed Two-Tailed PCR for ultrasensitive analysis of microRNAs based on products from Roche. Based on an innovative novel design with a RT primer sensing the microRNA using two connected hemi-probes exceeding sensitivity and superior specificity is achieved. The results of the work appeared in this week’s issue of the prestigious journal Nucleic Acids Research.

Mature microRNAs are single-stranded molecules only 22-24 nucleotides in length. They constitute a recently discovered class of non-coding RNAs that plays a key role in the regulation of gene expression. Many microRNAs are present in families that differ only in a single base position or terminal modification. Acting at the post-transcriptional level, microRNAs fine-tune the expression of many protein-encoding genes. microRNAs are present in tissues, but also in biofluids, where they are actively transported as reporter molecules. This feature makes microRNAs exceedingly attractive biomarkers and its use is currently being standardized by the European effort SPIDIA.

There are several techniques to measure microRNA levels with quantitative PCR, but current methods use conventional pairs of primers that each is 20-25 bases in lengths. To be able to amplify the short microRNAs they must be elongated, which often compromises sensitivity and specificity. The novel Two-tailed approach solves this problem by sensing the microRNA sequencing with two short hemiprobes. Neither hemiprobe is long enough to bind alone, but in the novel Two-Tailed design the hemiprobes are connected, which leads to cooperative binding, such that either both bind, which gives sufficient contact and stability, or neither binds. Since each hemiprobe is short, a mismatch in its binding site has major impact, leading to the enhanced specificity of the Two-tailed method.

Two-tailed PCR was compared to three other methods for microRNA detection and found to be more sensitive and specific, being capable to detect fewer than 10 microRNA molecules in a sample. Two-tailed PCR can be multiplexed to essentially any degree using 2-tube protocol and when using one-tube protocol multiplexing with probes is possible. Two-tailed PCR is one of the methods currently evaluated for microRNA detection in liquid biopsies collected for the management of cancer within the European effort Cancer-ID and for Sepsis within the European effort Smartdiagnos. Custom Two-tailed assays can be ordered.

Relaterade länkar

Ämnen

  • Epidemier

Kategorier

  • #qpcr
  • #diagnostics
  • #tataa
  • #two-tailedpcr
  • #microrna
  • #mir
  • #mirna

TATAA Biocenter grundades 2001 kring avancerad forskning och utveckling inom bioteknik vid Chalmers Tekniska högskola och utvecklar ultrakänsliga molekylära analysmetoder baserade på den skyddade tekniken Two-Tailed PCR. Genom avknoppningen Life Genomics erbjuds genetiska tester såsom icke-invasiv fosterdiagnostik, s.k. NIPT. Tidigare i år utsågs TATAA Biocenter till Europas främsta genanalysföretag av Global Health & Pharma

TATAA Biocenter var bland de första att utveckla ett test för SARS-COV-2, som registrerats för CE-IVD under namnet TATAA GrandPerformance SARS-COV-2 Detection kit för diagnostisk användning inom Europa. TATAA var också tidigt igång med testning för SARS-COV-2 i samarbete med Saint James Hospital på Malta. I Sverige erbjuder TATAA Biocenter testning till företag och privatpersoner genom Gendoktorn Medicinsk Service. VD Mikael Kubista förestår även ett akademiskt laboratorium vid BIOCEV i Prag, som deltar i Tjeckiens nationella SARS-COV-2 screening.

TATAA Biocenter ingår i konsortiet CORONADX, som erhållit 3 million euro från EUs forskningsprogram H2020 för att utveckla snabbtester för corona.

TATAA Biocenter ingår i det internationella konsortium SPIDIA4P, som tar fram underlag för europeiska och internationella riktlinjer och standards inom molekylär diagnostik. 

VD Mikael Kubista är en av författarna till MIQE-riktlinjerna för qPCR analys.

Kontakter

Mikael Kubista

Presskontakt CEO Cell and Gene Therapy +46733928168

Romina Cifliku

Presskontakt Project Manager +46 728815843

Relaterat innehåll